Schrödinger and TB Alliance Announce Collaboration to Accelerate Tuberculosis Drug Discovery
December 11, 2018 at 07:00 am
Share
Schrödinger and TB Alliance announced a three-year research collaboration to speed the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery. The joint team is focused on the discovery of efficacious inhibitors of PknB, which is essential for the growth of Mycobacterium tuberculosis (TB). Schrödinger’s computational platform has led the team to highly potent inhibitors with promising pharmacokinetic properties, after only a handful of design and optimization cycles. The next phase of the collaboration will involve in vivo efficacy studies and lead optimization to inform selection of a development candidate.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.